Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EQ CVE:GPH NASDAQ:MDNA NASDAQ:RGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEQEquillium$0.41+8.9%$0.36$0.27▼$1.50$13.61M1.86466,096 shs288,034 shsGPHGraphite OneC$0.71+2.9%C$0.77C$0.64▼C$1.07C$71.89M1.0272,303 shs20,070 shsMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsRGCRegencell Bioscience$15.29+11.6%$0.00$0.08▼$83.60$6.77B2.292.41 million shs1.35 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEQEquillium+8.90%+23.08%+21.99%-12.19%-54.39%GPHGraphite One+2.90%+4.41%-7.79%-22.83%+4.41%MDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%RGCRegencell Bioscience+11.61%-12.13%+1,528,999,900.00%+1,528,999,900.00%+1,528,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEQEquillium2.6968 of 5 stars3.24.00.00.02.41.70.6GPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARGCRegencell Bioscience0.3395 of 5 stars0.03.00.00.03.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEQEquillium 2.33Hold$3.00623.07% UpsideGPHGraphite One 0.00N/AN/AN/AMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideRGCRegencell Bioscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEQEquillium$41.10M0.36N/AN/A$0.54 per share0.77GPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ARGCRegencell BioscienceN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEQEquillium-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AMDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/ARGCRegencell Bioscience-$4.30MN/A0.00∞N/AN/AN/AN/AN/ALatest RGC, MDNA, GPH, and EQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q1 2025EQEquillium-$0.1850N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEQEquilliumN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEQEquilliumN/A2.702.70GPHGraphite One0.021.090.33MDNAMedicenna TherapeuticsN/A9.579.57RGCRegencell BioscienceN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEQEquillium27.05%GPHGraphite One0.07%MDNAMedicenna Therapeutics12.38%RGCRegencell Bioscience0.13%Insider OwnershipCompanyInsider OwnershipEQEquillium31.60%GPHGraphite One28.81%MDNAMedicenna Therapeutics33.10%RGCRegencell Bioscience2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEQEquillium4035.72 million24.43 millionNot OptionableGPHGraphite One20101.25 millionN/ANot OptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableRGCRegencell Bioscience10N/AN/AN/ARGC, MDNA, GPH, and EQ HeadlinesRecent News About These CompaniesRegencell Bioscience (NASDAQ:RGC) Shares Gap Up - Should You Buy?July 16 at 10:59 AM | marketbeat.comRegencell Bioscience (NASDAQ:RGC) Shares Gap Down - Here's What HappenedJuly 14 at 12:28 PM | marketbeat.comRegencell Bioscience (NASDAQ:RGC) Trading Down 7.8% - Time to Sell?July 9, 2025 | marketbeat.comRGC - Regencell Bioscience Holdings Ltd Executives | MorningstarJuly 8, 2025 | morningstar.comMRegencell Bioscience (RGC) Nosedives 19.8% on Profit-TakingJuly 8, 2025 | msn.comRegencell Bioscience Stock Volatility Continues MondayJuly 8, 2025 | msn.comRegencell Bioscience (NASDAQ:RGC) Stock Price Up 7.9% - Time to Buy?July 7, 2025 | marketbeat.comBest Chinese Stocks Worth Watching - July 6thJuly 6, 2025 | marketbeat.comChinese Stocks To Add to Your Watchlist - July 5thJuly 5, 2025 | marketbeat.comTop Chinese Stocks To Consider - July 4thJuly 4, 2025 | marketbeat.comRGC - Regencell Bioscience Holdings Ltd Financials | MorningstarJuly 3, 2025 | morningstar.comMRegencell stock rally returns as company blames short selling for volatilityJuly 3, 2025 | msn.comChinese Stocks To Add to Your Watchlist - July 3rdJuly 3, 2025 | marketbeat.comRegencell Bioscience Appoints New Independent Director Amid Board ChangesJune 30, 2025 | tipranks.comRegencell Bioscience Reports Improved Financial Results for First Half of 2025June 30, 2025 | tipranks.comMystery $42 billion Chinese medical fortune collapses in daysJune 27, 2025 | msn.comRegencell's 82,000% Surge: The $33 Billion Stock Rally That Nobody Can ExplainJune 27, 2025 | finance.yahoo.comRegencell Bioscience Holdings Limited (RGC) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRGC - Regencell Bioscience Holdings Ltd Price vs Fair Value | MorningstarJune 26, 2025 | morningstar.comMRegencell Bioscience (NASDAQ:RGC) Trading Down 3.5% - Here's WhyJune 26, 2025 | marketbeat.comRegencell Bioscience Holdings Ltd (RGC)June 22, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGC, MDNA, GPH, and EQ Company DescriptionsEquillium NASDAQ:EQ$0.41 +0.03 (+8.90%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$0.43 +0.02 (+3.88%) As of 05:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Graphite One CVE:GPHC$0.71 +0.02 (+2.90%) As of 07/16/2025 03:43 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.Medicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Regencell Bioscience NASDAQ:RGC$15.29 +1.59 (+11.61%) As of 07/16/2025 04:00 PM EasternRegencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
